Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 16, Issue 1, Pages 106-114
Publisher
Informa UK Limited
Online
2014-11-21
DOI
10.4161/15384047.2014.987062
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Methotrexate-bestatin interaction: Involvement of P-glycoprotein and organic anion transporters in rats
- (2014) Yanna Zhu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3
- (2014) Na Zhao et al. Molecular Cancer
- MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)
- (2013) Meng-Tao Ma et al. CANCER LETTERS
- Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin
- (2013) Xiaokui Huo et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Dioscin Restores the Activity of the Anticancer Agent Adriamycin in Multidrug-Resistant Human Leukemia K562/Adriamycin Cells by Down-Regulating MDR1 via a Mechanism Involving NF-κB Signaling Inhibition
- (2013) Lijuan Wang et al. JOURNAL OF NATURAL PRODUCTS
- Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
- (2012) Wen-jing Zhou et al. BRITISH JOURNAL OF PHARMACOLOGY
- H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2
- (2011) Ning Wei et al. BIOCHEMICAL PHARMACOLOGY
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo
- (2010) Y. Dai et al. BLOOD
- LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer
- (2010) Y.-L. Choi et al. CANCER RESEARCH
- The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
- (2010) Julia Salih et al. INTERNATIONAL JOURNAL OF CANCER
- Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
- (2009) Amit K. Tiwari et al. BIOCHEMICAL PHARMACOLOGY
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function
- (2009) Li-yang Tao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
- (2009) Chun-ling Dai et al. CANCER LETTERS
- Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
- (2009) Sandra E. Ghayad et al. INTERNATIONAL JOURNAL OF CANCER
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
- (2009) Li-sheng Zheng et al. PLoS One
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started